Nifedipine Tablets
Function and Efficacy
1. This product can simultaneously relax the coronary arteries in the normal blood supply area and the ischemic area, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase the delivery of myocardial oxygen to patients with coronary artery spasm, and relieve and prevent coronary artery spasm. 2. This product can inhibit myocardial contraction, reduce myocardial metabolism, and reduce myocardial oxygen consumption. 3. This product can relax peripheral resistance vessels, reduce peripheral resistance, and can reduce systolic and diastolic blood pressure, reducing cardiac afterload. 4. This product can delay the sinoatrial node function and atrioventricular conduction of the isolated heart; electrophysiological studies of whole animals and humans have not found that this product has the effect of delaying atrioventricular conduction, prolonging the recovery time of the sinoatrial node, and slowing down the sinoatrial node rate.
Ingredients
The main ingredient of this product and its chemical name are: 2,6-dimethyl-4(2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylic acid dimethyl ester.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| NifedipineIngredients |
1. It can simultaneously relax the coronary arteries in the normal blood supply area and the ischemic area, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase the delivery of myocardial oxygen in patients with coronary artery spasm, and relieve and prevent coronary artery spasm; 2. It can inhibit myocardial contraction, reduce myocardial metabolism, and reduce myocardial oxygen consumption; 3. It can relax peripheral resistance vessels, reduce peripheral resistance, reduce systolic and diastolic blood pressure, and reduce cardiac afterload; 4. It can delay the sinoatrial node function and atrioventricular conduction of the isolated heart; electrophysiological studies on whole animals and humans have not found that this product has the effect of delaying atrioventricular conduction, prolonging the recovery time of the sinoatrial node, and slowing down the sinoatrial node rate. More |
21829-25-4 | 74 |
Appearance
This product is a sugar-coated tablet, which appears yellow after removing the sugar coating.
Indication
1 Angina pectoris: variant angina pectoris; unstable angina pectoris; chronic stable angina pectoris. 2 Hypertension (alone or in combination with other antihypertensive drugs).
Usage and Dosage
1 The dose of nifedipine should be gradually adjusted according to the patient's tolerance and control of angina pectoris. Overdose of nifedipine can cause hypotension. 2 Start with a small dose, usually 10 mg/time, 3 times a day; the commonly used maintenance dose is 10-20 mg/time, 3 times a day. Some patients with obvious coronary spasm can use 20-30 mg/time, 3-4 times a day. The maximum dose should not exceed 120 mg/day. If the condition is urgent, 10 mg/time can be chewed or taken sublingually, and the decision to re-administer the drug depends on the patient's response to the drug. 3 It usually takes 7-14 days to adjust the dose. If the patient's symptoms are obvious and the condition is urgent, the dose adjustment period can be shortened. Depending on the patient's response to the drug, the frequency of attacks and the dose of sublingual nitroglycerin, the dose of nifedipine can be adjusted from 10-20 mg to 30 mg/time, 3 times a day within 3 days. 4 For hospitalized patients under strict monitoring, the dose can be increased by 10 mg every 4-6 hours, depending on the control of angina pectoris or ischemic arrhythmias.
Adverse Reactions
1 Common symptoms after taking the drug include peripheral edema (peripheral edema is related to the dose, the incidence is 4% when taking 60 mg/day, and 12.5% when taking 120 mg/day); dizziness; headache; nausea; fatigue and facial flushing (10%). Transient hypotension (5%), usually does not require discontinuation of the drug (transient hypotension is related to the dose, the incidence is 2% when taking 60 mg/day, and the incidence is 5% when taking 120 mg/day. Some patients may experience angina pectoris, which may be related to the hypotensive reaction. Palpitations; nasal congestion; chest tightness; shortness of breath; constipation; diarrhea; gastrointestinal cramps; abdominal distension; skeletal muscle inflammation; joint stiffness; muscle spasms; mental tension; tremors; nervousness; sleep disorders; blurred vision; imbalance, etc. (2%). Syncope (0.
Precautions
It is contraindicated in patients allergic to nifedipine.
Special Population Medication
Precautions for children: Not clear yet. Precautions for pregnancy and lactation: 1. No detailed clinical research data. Nifedipine is clinically used for pregnant women with hypertension. 2. Nifedipine can be secreted into breast milk, so lactating women should stop taking the drug or stop breastfeeding. Precautions for the elderly: The half-life of nifedipine is prolonged in the elderly, so pay attention to adjusting the dose when using it.
Drug Interactions
1. Nitrates are used in combination with this product to control angina attacks and are well tolerated. 2. Most patients with beta-receptor blockers have good tolerance and efficacy when using this product in combination, but some patients may induce and aggravate hypotension, heart failure and angina. 3. Digitalis This product may increase the blood digoxin concentration, suggesting that the blood concentration of digoxin should be monitored when using it for the first time, adjusting the dose or stopping this product. 4. When drugs with high protein binding rates such as dicoumarins, phenytoin sodium, quinidine, quinine, warfarin, etc. are used with this product, the free concentrations of these drugs often change. 5. When cimetidine is used with this product, the plasma concentration of this product increases, so pay attention to adjusting the dose.
Storage
Keep in a light-proof and airtight container.
Packaging Specification
10 mg
Validity Period
36 months.
Manufacturer
CSPC OUYI Pharmaceutical Co., Ltd.
-
Founded in:
2001-03-29 -
Address:
No. 88, Yangzi Road, Shijiazhuang Economic and Technological Development Zone -
Tax NO.:
91130100601289268L -
Registered Funds:
298 million yuan -
Website:
-
Email: